ADPT Stock News & Catalysts – Adaptive Biotechnologies

FEATURED

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the

Summary

Nov 4, 2026, 4:05 PM ·Globe Newswire

RECENT

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

Oct 14, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

Sep 25, 2026, 8:03 AM ·Globe Newswire

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred

Sep 17, 2026, 8:00 AM ·Globe Newswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

Sep 1, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the

Jul 29, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

Jul 9, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common

Jun 17, 2026, 6:00 AM ·Globe Newswire

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical

Jun 15, 2026, 4:10 PM ·Globe Newswire

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25

Jun 15, 2026, 4:05 PM ·Globe Newswire

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

May 29, 2026, 7:30 AM ·Globe Newswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

May 21, 2026, 4:17 PM ·Globe Newswire

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive

May 5, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

Apr 15, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive

Feb 5, 2026, 4:05 PM ·Globe Newswire

Adaptive Biotechnologies Corporation ADPT · News